Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing
NCT ID: NCT01964768
Last Updated: 2013-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
324 participants
INTERVENTIONAL
2010-12-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* 5 Grasses pollen,
* Birch pollen,
* Dermatophagoides pteronyssinus mite
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Skin prick-test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female subjects aged 5-60 years inclusive
* Female of childbearing potential must be on a reliable method of contraception and have a negative urine pregnancy test
* Presence of a clinical history of allergy: seasonal or perennial rhinitis, conjunctivitis and/or asthma during grass or birch pollen seasons (at least two pollen seasons) and/or due to mite exposure (at least two years)
* Subjects affiliated to a social security system
Exclusion Criteria
* Dermographism
* Absence of cutaneous reactivity
* Presence of cutaneous lesions on the forearms either preventing the performance of the test or potentially interfering with the interpretation of the test
* Subjects presenting unstable asthma or poor general health condition
* Subjects with past or current specific immunotherapy treatment for any of the 3 tested allergens (Grass, Birch pollens, D. pteronyssinus and/or D. farinae mites) in the previous 5 years
* Any oral antihistaminic treatment in the previous 3 days or 10 days in case of loratadine or desloratadine
* Subjects on anti-IgE treatment
* Subjects treated with beta-blockers and/or anti-depressives.
* Subjects currently participating in another clinical trial or still in exclusion period for a previous clinical trial
* Investigators, co-investigators, as well as their children or spouses and all the study collaborators
* Subjects under protection of the courts, legal guardianship or legal trusteeship
5 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stallergenes Greer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frédéric de Blay, Pr
Role: PRINCIPAL_INVESTIGATOR
Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DG40.08
Identifier Type: -
Identifier Source: org_study_id